|Bid||49.16 x 1000|
|Ask||50.01 x 1100|
|Day's range||49.17 - 49.78|
|52-week range||46.93 - 58.10|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||18.48|
|Forward dividend & yield||1.75 (3.51%)|
|Ex-dividend date||26 May 2022|
|1y target est||N/A|
Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.
GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.